Crucell and DSM Announce PER.C6 Licensing Agreement with GlaxoSmithKline for Monoclonal Antibody Production
13. August 2004 02:08 ET
|
Crucell N.V.
LEIDEN, The Netherlands, Aug. 13, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that...
Crucell Announces Second Quarter 2004 Results
09. Juli 2004 04:41 ET
|
Crucell N.V.
LEIDEN, The Netherlands, July 9, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) today announced its financial results for the second quarter of 2004....
Crucell -- DSM Biologics Alliance Announces Development Milestone Achievement
07. Juli 2004 02:16 ET
|
Crucell N.V.
LEIDEN/SITTARD, The Netherlands, July 7, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today the...
GlaxoSmithKline Renews PER.C6(R) License Agreement with Crucell
06. Juli 2004 02:14 ET
|
Crucell N.V.
LEIDEN, The Netherlands, July 6, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that GlaxoSmithKline has decided to renew its PER.C6(R)...
Crucell Discovers Human Monoclonal Antibody that Protects Against SARS
25. Juni 2004 02:08 ET
|
Crucell N.V.
LEIDEN, The Netherlands, June 25, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today the discovery of an antibody for protection against SARS...
Crucell and DSM Announce PER.C6(R) Licensing Agreement with Chiron for Monoclonal Antibody Production
15. Juni 2004 02:12 ET
|
Crucell N.V.
LEIDEN/SITTARD, The Netherlands, June 15, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today...
Crucell and DSM Announce PER.C6(R) Licensing Agreement with Merus for Production of Monoclonal Antibody Combinations
10. Juni 2004 02:10 ET
|
Crucell N.V.
LEIDEN/SITTARD, The Netherlands, June 10, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today...
Crucell to Present at Needham & Company Third Annual Biotechnology Conference, June 16
09. Juni 2004 08:15 ET
|
Crucell N.V.
LEIDEN, Netherlands, June 9, 2004 (PRIMEZONE) -- Crucell N.V. (Nasdaq:CRXL) has announced its Chief Financial Officer, Leonard Kruimer, will present at the Annual Needham & Company Biotechnology...
Crucell and DSM Announce PER.C6(R) Licensing Agreement with PanGenetics for Monoclonal Antibody Production
08. Juni 2004 02:19 ET
|
Crucell N.V.
LEIDEN/SITTARD, The Netherlands, June 8, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that...
Market authorization for PER.C6(R)-based West Nile virus veterinary vaccine in Israel
03. Juni 2004 08:13 ET
|
Crucell N.V.
LEIDEN, The Netherlands, June 3, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) has announced market authorization for a West Nile virus veterinary vaccine...